ライフサイエンスコーパス: systolic heart failure

1 d to reduce hospitalization and mortality in systolic heart failure.

2 nd is at least as common in the community as systolic heart failure.

3 that is in clinical trials for treatment of systolic heart failure.

4 ailability and muscle power in patients with systolic heart failure.

5 iorespiratory fitness (CRF) in patients with systolic heart failure.

6 ure in patients with decompensated end-stage systolic heart failure.

7 ure in patients with decompensated end-stage systolic heart failure.

8 reasingly prevalent in patients with chronic systolic heart failure.

9 vabradine reduces afterload of patients with systolic heart failure.

10 ct of isolated HR reduction in patients with systolic heart failure.

11 ardiac contractility is a central feature of systolic heart failure.

12 ivator, omecamtiv mecarbil, in patients with systolic heart failure.

13 n may provide a new therapeutic approach for systolic heart failure.

14 rral cohort representing a broad spectrum of systolic heart failure.

15 stic and prognostic utility in patients with systolic heart failure.

16 ing is the principal cause of progression of systolic heart failure.

17 in children and adolescents with symptomatic systolic heart failure.

18 having symptoms that could be attributed to systolic heart failure.

19 emerged as an important therapy for advanced systolic heart failure.

20 art failure hospitalization in patients with systolic heart failure.

21 e, and reduced cost of care in patients with systolic heart failure.

22 trial was conducted of 6800 outpatients with systolic heart failure.

23 prognostic implications among patients with systolic heart failure.

24 rom 39 patients with decompensated end-stage systolic heart failure (92% male), aged 56 +/- 13 years.

25 Among patients with chronic systolic heart failure, a modest increase in peak VO(2)

26 daily with placebo in patients with ischemic systolic heart failure according to baseline high sensit

27 In patients with systolic heart failure and a QRS duration of less than 1

28 Patients with systolic heart failure and anemia have worse symptoms, f

29 n alfa on clinical outcomes in patients with systolic heart failure and anemia.

30 Fifty-three patients with systolic heart failure and bundle-branch block underwent

31 valuated and is used in select patients with systolic heart failure and chronic stable angina without

32 use of escitalopram in patients with chronic systolic heart failure and depression.

33 We studied 11 patients with systolic heart failure and left bundle-branch block sche

34 of ventricular systole are characteristic of systolic heart failure and might be improved by a new th

35 In patients with systolic heart failure and mild symptoms, eplerenone red

36 -blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemo

37 t improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia.

38 ion (CRT) prolongs survival in patients with systolic heart failure and QRS prolongation.

39 iews data from randomized clinical trials in systolic heart failure and the interactions between base

40 eatment for patients with moderate to severe systolic heart failure and ventricular dyssynchrony.

41 ents that clinically have both diastolic and systolic heart failure and will soon become the most com

42 ined ventricular tachycardia with syncope or systolic heart failure as a result of ischemic or nonisc

43 ntagonists improve outcomes in patients with systolic heart failure but may induce worsening of renal

44 om those with a depressed ejection fraction (systolic heart failure), but echocardiography can.

45 ced intracellular aggregate accumulation and systolic heart failure by 12 months.

46 an exercise training trial for patients with systolic heart failure, cardiopulmonary exercise tests w

47 brillator (ICD) in patients with symptomatic systolic heart failure caused by coronary artery disease

48 Among the patients with systolic heart failure (ejection fraction </=35%) random

49 m coenzyme Q in 1,191 patients with ischemic systolic heart failure enrolled in CORONA (Controlled Ro

50 y profile) in patients with mild symptoms of systolic heart failure, even in those already receiving

51 s with New York Heart Association class I/II systolic heart failure exhibit left ventricular (LV) rev

52 61 children and adolescents with symptomatic systolic heart failure from 26 US centers.

53 h greater proportional representation in the systolic heart failure group; all 12 SNPs were confirmed

54 Common or sporadic systolic heart failure (heart failure) is the clinical s

55 ished adjunctive treatment for patients with systolic heart failure (HF) and ventricular dyssynchrony

56 ng at night ("sleep apnea") in patients with systolic heart failure (HF) have failed to improve progn

57 Exercise training in patients with systolic heart failure (HF) is an accepted adjunct to an

58 ls present in the setting of chronic, stable systolic heart failure (HF) is unclear.

59 ommend digoxin for patients with symptomatic systolic heart failure (HF) receiving optimal medical th

60 remodeling associated with the transition to systolic heart failure (HF) were examined in the spontan

61 Patients with systolic heart failure (HF) who develop secondary pulmon

62 Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriu

63 ss disease severity in patients with chronic systolic heart failure (HF).

64 parameter that potently predicts outcomes in systolic heart failure (HF).

65 nical outcomes in patients hospitalized with systolic heart failure (HF).

66 recovery after exercise among patients with systolic heart failure (HF).

67 tractile failure during cardiac ischemia and systolic heart failure, in part due to decreased excitat

68 Advanced systolic heart failure is associated with myocardial and

69 Systolic heart failure is characterized by ventricular d

70 transplantation as soon as the diagnosis of systolic heart failure is established.

71 and other procedures in patients with severe systolic heart failure is unclear.

72 trolled trial, 556 patients with symptomatic systolic heart failure (left ventricular ejection fracti

73 CD implantation in patients with symptomatic systolic heart failure not caused by coronary artery dis

74 In patients with systolic heart failure not caused by ischemic heart dise

75 Patients with non-systolic heart failure (NS-CHF) had significantly lower

76 echocardiographic analysis in patients with systolic heart failure obtained from a variety of invest

77 efibrillators] in Patients With Non-Ischemic Systolic Heart Failure on Mortality) did not demonstrate

78 METHODS AND We studied 2231 adult systolic heart failure patients (27% of whom were women)

79 ducted a randomized, controlled trial of 223 systolic heart failure patients and compared the effects

80 Among systolic heart failure patients referred for PET/FDG, ea

81 In a multicenter cohort of 1513 chronic systolic heart failure patients, we measured a contempor

82 ment of patients with moderately symptomatic systolic heart failure, patients experienced thromboembo

83 In systolic heart failure, reduction in relatively high hea

84 ansplantation in ESRD patients with advanced systolic heart failure results in an increase in LVEF, i

85 ontrols and 1,117 Caucasian individuals with systolic heart failure revealed 12 SNPs in the cardiovas

86 gnificantly lower BNP levels than those with systolic heart failure (S-CHF) (413 pg/ml vs. 821 pg/ml,

87 e retrospective cohort had 664 patients with systolic heart failure (SHF) and 399 patients with diast

88 ol group of 35 subjects and 60 patients with systolic heart failure (SHF) were included for compariso

89 h carries similar morbidity and mortality to systolic heart failure (SHF).

90 uretic peptide (BNP) levels in patients with systolic heart failure (SHF).

91 Among patients with systolic heart failure, sinus rhythm, and heart rate >/=

92 enefit of prophylactic ICDs in patients with systolic heart failure that is not due to coronary arter

93 In decompensated patients with advanced systolic heart failure, tissue Doppler-derived mitral E/

94 This study used the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor

95 o either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor I

96 vabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure Treatment With the IF Inhibitor I

97 Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial results.

98 prevention ICD in patients with nonischemic systolic heart failure warrants further investigation.

99 ure in patients with decompensated end-stage systolic heart failure was recently challenged, but the

100 In 110 patients with systolic heart failure, we evaluated the correlation bet

101 Patients hospitalized for systolic heart failure were randomly assigned to HNC or

102 au patterns may be observed in patients with systolic heart failure who cannot further increase .Q at

103 tors (PROSe-ICD) enrolled 1189 patients with systolic heart failure who underwent ICD implantation fo

104 Twelve male patients with stable systolic heart failure whose initial polysomnograms show

105 ) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.

106 ose (LDL concentration) for the treatment of systolic heart failure with statin therapy.